Differential Expression of CD30 on CD3 T Lymphocytes in Patients with Systemic Lupus Erythematosus

Scandinavian Journal of Immunology

Volumn 78, Issue 3, 2013, Pages 306-312

  Cabrera, C M ^a   Urra, J M ^a   Carreno A ^a   Zamorano, J ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^b HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIGENS, CD3; ANTIGENS, CD30; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-8; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; T-LYMPHOCYTE SUBSETS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84883041534     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12088     Document Type: Article

References (40)

1. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 2003;10:267-71.
2. Ellis TM, Simms PE, Slivnick DJ, Jäck HM, Fisher RI. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993;151:2380-9.
3. Del Prete G, De Carli M, Almerigogna F et al. Preferential expression of CD30 by human CD4 T cells producing Th2-type cytokines. FASEB 1995;9:81-6.
4. Leonard C, Tormey V, Burke C, Poulter LW. Allergen induced cytokine production in atopic diseases and its relationship to disease severity. Am J Respir Cell Mol Biol 1997;17:368-75.
5. Nakamura T, Lee RK, Nam SY et al. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. J Immunol 1997;158:2090-8.
6. Gilfillan MC, Noel PJ, Paddock ER, Reiner SL, Thompson CB. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998;160:2180-7.
7. Agrawal B, Reddish MA, Longenecker BM. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 1996;157:3229-34.
8. Rossi FM, Degan M, Mazzocut-Zecchin L et al. CD30L up-regulates CD30 and IL-4 expression by T cells. FEBS Lett 2001;508:418-22.
9. Stanciu LA, Roberts K, Lau LCK, Coyle AJ, Johnston SL. Induction of type 2 activity in adult human CD8 T cells by repeated stimulation and IL-4. Int Immunol 2001;13:341-8.
10. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (TH2) responses. J Leukoc Biol 1995;57:726-30.
11. Del Prete G, Maggi E, Pizzolo G, Romagnani S. CD30, TH2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 1995;16:76-80.
12. Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol 2009;647:174-85.
13. Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leuk Lymphoma 2011;52:1641-54.
14. Caligaris-Cappio F, Bertero MT, Converso M et al. Circulating levels of soluble CD30 a marker of cells producing TH2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995;13:339-43.
15. Ciferská H, Horák P, Hermanová Z et al. The levels of sCD30 and sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol 2007;26:723-8.
16. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
17. Yee CS, Farewell VT, Isenberg DA et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology 2011;50:982-8.
18. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
19. Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology 2010;49:2243-54.
20. Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CGM, Abdulahad WH. Disturbed Th1, Th2, Th17 and Treg balance in patients with systemic lupus erythematosus. Clin Immunol 2011;141:197-204.
21. De la Torre M, Urra JM, Blanco J. Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity? Lupus 2009;18:216-22.
22. Mellor-Pita S, Citores MJ, Castejón R et al. Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in Systemic Lupus Erythematosus. Cytometry B Clin Cytom 2009;76:261-70.
23. De la Torre M, Alcázar R, Sánchez de la Nieta D, Nieto J, Ferreras I, Urra JM. Lupus relapse after prostaglandin E1 administration: activation of a cytokine cascade? Ann Rheum Dis 2002;61:91-2.
24. Podack ER, Strbo N, Sotosec V, Muta H. CD30-governor of memory T cells? Ann NY Acad Sci 2002;975:101-13.
25. Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006;118:143-52.
26. Hoffman RW. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 2004;113:4-13.
27. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGFβ. J Biochem 2010;147:781-92.
28. Buckner JH. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849-59.
29. Gerli R, Nocentini G, Alunno A et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 2009;8:426-30.
30. Becker-Merok A, Eilertsen GØ, Nossent JC. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J Rheumatol 2010;37:2039-45.
31. Edelbauer M, Kshirsagar S, Riedl M et al. Activity of childhood lupus nephritis is linked to altered T cell and cytokine homeostasis. J Clin Immunol 2012;32:477-87.
32. high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006;65:1512-7.
33. Yang PT, Kasai H, Zhao LJ, Xiao WG, Tanabe F, Ito M. Increased CCR4 expression on circulating CD4+ T cells in ankylosing spondylitis, rheumatoid arthritis and LES. Clin Exp Immunol 2004;138:342-7.
34. Verthelyi D, Petri M, Ylamus M, Klinman DM. Disassociation of sex hormone levels and cytokine production in SLE patients. Lupus 2001;10:352-8.
35. Wang Y, Ito S, Chino Y et al. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol 2010;159:1-10.
36. Chen YB, McDonough S, Hasserjian R et al. Expression of CD30 in patients with acute graft-versus-host disease. Blood 2012;120:691-6.
37. Yu Y, Wang D, Liu C et al. Prevention of GVHD while sparing GLV effect by targeting Th1 and Th17 transcription factor T-beta and RORyt in mice. Blood 2011;118:5011-20.
38. Ulusoy H, Kamanli A, Ilhan N et al. Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis. Rheumatol Int 2012;32:3857-62.
39. Sun X, Yamada H, Shibata K et al. CD30 ligand/CD30 plays a crucial role in Th17 differentiation in mice. J Immunol 2010;185:2222-30.
40. Sun X, Yamada H, Shibata K et al. CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J Immunol 2010;185:7671-80.